Home » Newsletters » BioWorld Science

BioWorld Science

June 18, 2021

View Archived Issues

PureTech advances its wholly owned pipeline

Phase II results presented for ZYN-002 in children and adolescents with DEE

BriaCell advances personalized immunotherapies for prostate cancer, melanoma and lung cancer

FDA accepts IND for phase I trial of Xilio's XTX-101 in solid tumors

Algernon plans phase I study of AP-188 for stroke

Akaal reports preclinical data on AK-119 in neuropathic pain

Modus collaborates with Imperial College London on clinical study of sevuparin in malaria

Harbour BioMed begins phase I dosing with HBM-4003 in NSCLC

Satsuma reports phase I safety and PK data on STS-101

4SC and NKI collaborate to study neoadjuvant domatinostat in urothelial carcinoma

Amgen synthesizes new fatty acid desaturase 1 inhibitors

Daewoong Pharmaceutical patents JAK3 inhibitors

Aurigene Discovery Technologies presents new CD73 inhibitors

Chinese investigators describe new JAK inhibitors

Alnylam Pharmaceuticals divulges ATXN3-targeting ds-siRNAs

Phase I data for the novel first-in-class anti-SIRPalpha antibody, BI-765063

177Lu-DOTAGA.(SA.FAPi)2 use for thyroid cancer

Viking reports phase I data on TRbeta agonist VK-0214

New basket trial evaluates spartalizumab in tumors with high PD-1 expression levels

Reversible BTK inhibitors from Hyperway described

HSV-targeting compound affects latent infection

Anji licenses rights to MCL1 inhibitor program from Broad Institute

Histopathology data reported for TATX-03a in SARS-CoV-2 challenged hamsters

Kite and ShoreLine Biosciences partner on allogeneic cell therapies for hematologic malignancies

Qpex opens phase I study of QPX-9003 for infections caused by drug-resistant Gram-negative pathogens

Evaluation of DAN-222 alone or in combination with PARP inhibitor in models of breast cancer

Increased PARP activity in PBLs could predict prostate cancer susceptibility

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...